These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38499495)

  • 21. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Calcimimetics: physiology, results of preclinical and clinical studies, and perspectives].
    Torres PU
    Nephrol Ther; 2011 Apr; 7(2):99-104. PubMed ID: 21310676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism.
    Block GA; Chertow GM; Sullivan JT; Deng H; Mather O; Tomlin H; Serenko M
    PLoS One; 2019; 14(3):e0213774. PubMed ID: 30875390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis.
    Warady BA; Ng E; Bloss L; Mo M; Schaefer F; Bacchetta J
    Pediatr Nephrol; 2020 Sep; 35(9):1679-1697. PubMed ID: 32367309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study.
    Morosetti M; Jankovic L; Zappalà L; Agafonova E; Pryshlyak I
    Int Urol Nephrol; 2023 Jul; 55(7):1865-1873. PubMed ID: 36790677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis.
    Zhang Q; Li M; You L; Li H; Ni L; Gu Y; Hao C; Chen J
    PLoS One; 2012; 7(10):e48070. PubMed ID: 23133549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ?
    Eidman KE; Wetmore JB
    Semin Dial; 2018 Sep; 31(5):440-444. PubMed ID: 30009474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.
    Warady BA; Iles JN; Ariceta G; Dehmel B; Hidalgo G; Jiang X; Laskin B; Shahinfar S; Vande Walle J; Schaefer F
    Pediatr Nephrol; 2019 Mar; 34(3):475-486. PubMed ID: 30506144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of the Calcium Receptor by Calcimimetic Agents Is Preserved Despite Modest Attenuating Effects of Hyperphosphatemia.
    Goodman WG; Ward DT; Martin KJ; Drayer D; Moore C; Xu J; Lai J; Chon Y; Nemeth EF
    J Am Soc Nephrol; 2022 Jan; 33(1):201-212. PubMed ID: 34732508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
    Bucharles SGE; Barreto FC; Riella MC
    J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Fukagawa M; Shimazaki R; Akizawa T;
    Kidney Int; 2018 Oct; 94(4):818-825. PubMed ID: 30049473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etelcalcetide for the treatment of secondary hyperparathyroidism.
    Hamano N; Komaba H; Fukagawa M
    Expert Opin Pharmacother; 2017 Apr; 18(5):529-534. PubMed ID: 28277829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.
    Li D; Shao L; Zhou H; Jiang W; Zhang W; Xu Y
    Endocrine; 2013 Feb; 43(1):68-77. PubMed ID: 22669774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of calcimimetics on long-term outcomes in dialysis patients: literature review and Bayesian meta-analysis.
    Lozano-Ortega G; Waser N; Bensink ME; Goring S; Bennett H; Block GA; Chertow GM; Trotman ML; Cooper K; Levy AR; Belozeroff V
    J Comp Eff Res; 2018 Jul; 7(7):693-707. PubMed ID: 29762046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of accessibility to non-calcium-based phosphate binders and calcimimetics on mineral outcomes in patients receiving maintenance hemodialysis: A 10-year retrospective analysis of real-world data.
    Disthabanchong S; Kasempin P; Srisuwarn P; Chansomboon P; Buachum N
    PLoS One; 2024; 19(5):e0304649. PubMed ID: 38820324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
    N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy.
    Strippoli GF; Palmer S; Tong A; Elder G; Messa P; Craig JC
    Am J Kidney Dis; 2006 May; 47(5):715-26. PubMed ID: 16632010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calcimimetic use in US hemodialysis facilities in first 2 years after the launch of etelcalcetide: A descriptive analysis of real-world clinical practice and outcomes.
    Stephens JM; Fox KM; Desai P; Cheng S; Goodman WG; Kendrick JB
    Hemodial Int; 2022 Apr; 26(2):243-254. PubMed ID: 34931443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological profile of upacicalcet, a novel positive allosteric modulator of calcium-sensing receptor, in vitro and in vivo.
    Goto M; Nishimura G; Sato H; Yamaguchi Y; Morimoto N; Hashimoto H; Takahashi N
    Eur J Pharmacol; 2023 Oct; 956():175936. PubMed ID: 37541363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.